Form 4: Cytokinetics EVP Fady Ibraham Malik Reports Stock Transactions
SEC Form 4
EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the exercise of stock options and subsequent sale of shares on April 22, 2025.
Summary
- On April 22, 2025, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., exercised non-qualified stock options to acquire 2,000 shares of common stock at a price of $10.60 per share.
- Simultaneously, Malik sold 2,000 shares of common stock at a price of $38.11 per share.
- Following these transactions, Malik directly owns 140,255 shares of Cytokinetics Inc.
- Malik also directly owns 25,105 non-qualified stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock transactions. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the buying and selling activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 03/28/2017 | Date the Non-Qualified Stock Option became exercisable |
| 02/28/2027 | Expiration date of the Non-Qualified Stock Option |
| 04/22/2025 | Date of stock option exercise and sale of shares |
Keywords
Cytokinetics, Stock Options, Form 4, Insider Trading, Equity, Malik, CYTK, Shares, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.